ArticleResearch square2026
Targeting Tumour Microtubes to Disrupt Glioma Networks.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Glioma cells form multicellular communication networks through tumour microtubes (TMs), integrating tumour-tumour and neuron-tumour connectivity to sustain growth and therapy resistance. Underlying molecular regulation of TMs and potential targeting strategies have proven elusive. Here, we demonstrate that glioma stem cells (GSCs) preferentially grow TMs, which locally synthesize neurotransmitter receptors and metabolic enzymes to support network communication. Coordinated proteomics and functional screening of TMs identified inner mitochondrial component, FASTKD2, as essential to local protein synthesis. Targeting FASTKD2 attenuates tumour stemness and growth, disrupting coordinated mitochondrial RNA metabolism in TMs, which sustains intercellular communication and tumour proliferation. Structure-function screening revealed antibiotic linezolid inhibited FASTKD2 interactions with mitochondrial RNA, thereby disrupting tumour network communication and augmenting efficacy of therapies targeting neuronal stimulation of tumour cells. Collectively, tumour cells coopt features of neuronal cell biology, including localized protein synthesis, to reinforce TM-mediated glioma network communication, generating therapeutic vulnerabilities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.